Sistema de Salut de Catalunya
Institut Català de la Salut
[García-Fortes M] Hematology Department, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain. Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain. [Hernández-Boluda JC] Hematology Department, Hospital Clínico, INCLIVA, 46010 Valencia, Spain. [Álvarez-Larrán A] Hematology Department, Hospital Clínic, 08036 Barcelona, Spain. [Raya JM] Hematology Department, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain. [Angona A] Hematology Department, Hospital del Mar, 08003 Barcelona, Spain. [Estrada N] Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain. [Fox L] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-06T12:05:49Z
2022-09-06T12:05:49Z
2022-05
Comorbidities; Myelofibrosis; Survival
Comorbilidades; Mielofibrosis; Supervivencia
Comorbiditats; Melofibrosi; Supervivència
The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.
This research was supported by an unrestricted grant from Novartis Pharmaceutical. The opinions expressed in this article are those of the authors and do not necessarily reflect those of Novartis.
Article
Published version
English
Comorbiditat; Mielofibrosi - Prognosi; Anàlisi de supervivència (Biometria); DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Primary Myelofibrosis; PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::mielofibrosis primaria; SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia
MDPI
Cancers;14(9)
https://doi.org/10.3390/cancers14092331
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
